Completed PHASE1 INTERVENTIONAL 2-arm NCT04779892

The Study of Infliximab (CMAB008 and Remicade) in Healthy Subjects to Compare the PK and Safety

Sponsor: Taizhou Mabtech Pharmaceutical Co.,Ltd

Interventions Infliximab

Updated 4 times since 2021 Last updated: Oct 8, 2021 Started: Feb 1, 2020 Primary completion: Jun 15, 2020 Completion: Jun 15, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Rheumatoid Arthritis, this trial is completed. The trial is conducted by Taizhou Mabtech Pharmaceutical Co.,Ltd and has accumulated 4 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Nov 2021 — Jul 2024 [monthly]

Completed PHASE1
Apr 2021 — Nov 2021 [monthly]

Completed PHASE1

First recorded

Feb 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Taizhou Mabtech Pharmaceutical Co.,Ltd

Data source: Taizhou Mabtech Pharmaceutical Co.,Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China